Gates Foundation extends TB research grant

Collaborative Drug Discovery, Inc., announced on Thursday that its grant from the Bill & Melinda Gates Foundation has been extended in order to create a novel database to enhance collaborative efforts to discover more effective tuberculosis drugs.

The CDD TB database has combined the efforts of non-profit, corporate, academic and government laboratories worldwide in an effort to accelerate the discovery of new therapies against TB, which kills over 1.5 million people each year.

The CDD hopes to play a critical role in the next three years to facilitate collaborations among the leading TB researchers, including three major pharmaceutical companies. The CDD will support workflows of screening centers and allow the secure sharing of data between labs to catalyze drug discovery.

"For six years, CDD has focused on supporting humanitarian as well as commercial drug discovery," Barry Bunin, the CEO and president of CDD, said. "Now we are excited to put our new CDD Projects technology to the test. CDD Projects enables natural yet secure real-time collaborations among researchers that mimics the way people work in the pharmaceutical industry."

"This project has enabled the creation of a unique database of well over 300,000 molecules with screening data against Mycobacterium tuberculosis," Sean Ekins, PhD, Director of Collaborations, said, "We have also collected literature data and patent information for many compounds and freely shared this data with the research community. In addition we have enabled many groups to store and share their small molecule screening data, securely over the Internet 'in the cloud' using unique proprietary technologies."

The Bill & Melinda Gates Foundation has extended the TB project to five years and has increased the amount of the grant total to $2,796,000.